Gene Expression Comparison of Pleomorphic Lobular Carcinoma In-Situ with Classical Lobular Carcinoma In-Situ and High-Grade Ductal Carcinoma In-Situ PLCIS gene expression
Abstract
Background: PLCIS shares histologic features with both cLCIS and hgDCIS, leading to ambiguity on optimal clinical management. Retrospective gene expression profiling and analysis were used to explore the relative biological behavior of PLCIS to cLCIS and hgDCIS.
Methods: This is a retrospective study. 16 PLCIS specimens, 10 cLCIS specimens, and 9 hgDCIS cases were included; gene expression using a 725 cancer-related gene expression assay was measured.
Results: PLCIS gene expression profile had greater overlap with cLCIS than hgDCIS. E2F target genes were upregulated in PLCIS compared to cLCIS, while glycolysis genes and interferon-α genes were upregulated in hgDCIS relative to PLCIS.
Conclusion: Although gene set analysis suggests PLICS could have more aggressive behavior than cLCIS, gene expression profiling suggests it has closer biological behavior to cLCIS than to hgDCIS. Long-term clinical outcome studies are still needed to determine prognosis and optimal management.
Full text article
References
Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol. 2014 Aug 10;5(3):546–53. doi:10.5306/wjco.v5.i3.546 PubMed PMID: 25114868.
Harrison BT, Nakhlis F, Dillon DA, Soong TR, Garcia EP, Schnitt SJ, et al. Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Mod Pathol. 2020 Jul;33(7):1287–97. doi:10.1038/s41379-020-0459-6 PubMed PMID: 31932682.
Shamir ER, Chen YY, Krings G. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. Mod Pathol. 2020 Jun;33(6):1078–91. doi:10.1038/s41379-019-0449-8 PubMed PMID: 31907376.
Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW. Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013;19(1):116–8. doi:10.1111/tbj.12062 PubMed PMID: 23231019.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139–40. doi:10.1093/bioinformatics/btp616 PubMed PMID: 19910308.
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015 Dec 23;1(6):417–25. doi:10.1016/j.cels.2015.12.004 PubMed PMID: 26771021.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739–40. doi:10.1093/bioinformatics/btr260 PubMed PMID: 21546393.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003 Jul;34(3):267–73. doi:10.1038/ng1180 PubMed PMID: 12808457.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545–50. doi:10.1073/pnas.0506580102 PubMed PMID: 16199517.
Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: Beyond the migration of single cells. J Biol Chem. 2020 Feb 21;295(8):2495–505. doi:10.1074/jbc.REV119.007759 PubMed PMID: 31937589.
Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004 Dec 8;23(24):4709–16. doi:10.1038/sj.emboj.7600481 PubMed PMID: 15538380.
Gao Y, Qiao X, Liu Z, Zhang W. The role of E2F2 in cancer progression and its value as a therapeutic target. Front Immunol. 2024;15:1397303. doi:10.3389/fimmu.2024.1397303 PubMed PMID: 38807594.
Iglesias-Ara A, Westendorp B. Editorial: The role of E2F transcription factors in cancer. Front Oncol. 2023;13:1355610. doi:10.3389/fonc.2023.1355610 PubMed PMID: 38239640.
Nikonezhad B, Lotfian M, Manavi N, Zamani A, Mahdevar M. Insights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses. Cancer Cell Int. 2025 Jun 6;25(1):203. doi:10.1186/s12935-025-03839-2 PubMed PMID: 40481544.
Yu L, Chen X, Sun X, Wang L, Chen S. The Glycolytic Switch in Tumors: How Many Players Are Involved? J Cancer. 2017;8(17):3430–40. doi:10.7150/jca.21125 PubMed PMID: 29151926.
Zhou D, Duan Z, Li Z, Ge F, Wei R, Kong L. The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front Pharmacol. 2022;13:1091779. doi:10.3389/fphar.2022.1091779 PubMed PMID: 36588722.
Du T, Zhu L, Levine KM, Tasdemir N, Lee A V, Vignali DAA, et al. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep. 2018 May 8;8(1):7205. doi:10.1038/s41598-018-25357-0 PubMed PMID: 29739984.
Benguigui M, Cooper TJ, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell. 2024 Feb 12;42(2):253-265.e12. doi:10.1016/j.ccell.2023.12.005 PubMed PMID: 38181798.
Shi W, Yao X, Fu Y, Wang Y. Interferon-α and its effects on cancer cell apoptosis. Oncol Lett. 2022 Jul;24(1):235. doi:10.3892/ol.2022.13355 PubMed PMID: 35720476.
Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13631–6. doi:10.1073/pnas.250477397 PubMed PMID: 11095741.
Gomez D, Reich NC. Stimulation of primary human endothelial cell proliferation by IFN. J Immunol. 2003 Jun 1;170(11):5373–81. doi:10.4049/jimmunol.170.11.5373 PubMed PMID: 12759411.
Martin-Hijano L, Sainz B. The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. Front Immunol. 2020;11:526. doi:10.3389/fimmu.2020.00526 PubMed PMID: 32296435.
Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, Coca S. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol. 2020;2020:9258396. doi:10.1155/2020/9258396 PubMed PMID: 32211045.
Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Ghaedi K. Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells. Front Oncol. 2020;10:452. doi:10.3389/fonc.2020.00452 PubMed PMID: 32426267.
Shah V, Nowinski S, Levi D, Shinomiya I, Kebaier Ep Chaabouni N, Gillett C, et al. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. Breast Cancer Res. 2017 Jan 17;19(1):7. doi:10.1186/s13058-016-0789-y PubMed PMID: 28095868.
Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010 Jul 15;70(14):5674–8. doi:10.1158/0008-5472.CAN-08-2660 PubMed PMID: 20551053.
Yee G, Wu R, Ishikawa T, Takabe K. Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers. World J Oncol. 2025 Oct;16(5):446–56. doi:10.14740/wjon2529 PubMed PMID: 41030644.
Tamayo P, Steinhardt G, Liberzon A, Mesirov JP. The limitations of simple gene set enrichment analysis assuming gene independence. Stat Methods Med Res. 2016 Feb;25(1):472–87. doi:10.1177/0962280212460441 PubMed PMID: 23070592.
Zhang J, Coombes KR. Sources of variation in false discovery rate estimation include sample size, correlation, and inherent differences between groups. BMC Bioinformatics. 2012;13 Suppl 13(Suppl 13):S1. doi:10.1186/1471-2105-13-S13-S1 PubMed PMID: 23320794.
Authors
Copyright (c) 2026 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.